


Extremity thrombosis


Updated: 4/1/2018

1. [Upper extremity VTE](#)
2. [Lower extremity VTE](#)
3. [Inferior vena cava \(IVC\) filter](#)
4. [Leg veins](#)
5. [Arm veins](#)
6. [Anticoagulant dosing](#)
7. [Bleeding risk calculators](#)
8. [References](#)

Upper extremity VTE




Lower extremity VTE




Inferior vena cava (IVC) filters

- Only two RCTs exist evaluating efficacy of IVC filters![10,11](#)
- Data is lacking to justify IVC filter use in majority of proposed scenarios¹²



Leg veins⁹




[Return to lower extremity thrombosis](#)

[Table of contents](#)

Arm veins


Superficial & Deep Veins of Upper Limb



[Return to upper extremity thrombosis](#)

[Table of contents](#)

Oral anticoagulant dosing for VTE



Bleeding risk calculators

Important notes:

- No bleeding risk tools have been validated for VTE treatment, only for prophylaxis and atrial fibrillation
- Observational studies suggest net clinical benefit of anticoagulation even with very high bleeding risk
- No RCTs exist demonstrating benefit of *withholding* anticoagulation based on high bleeding risk

HAS-BLED (atrial fibrillation) 1 point each	IMPROVE (VTE prophylaxis for inpatients)
HTN (SBP >165 mmHg)	Active gastroduodenal ulcer (4.5)
Renal disease (ESRD, Cr >2.26, or transplant)	Bleeding within past 3 months (4)
Liver disease (cirrhosis, AST/ALT >3x upper limit, Tbili >2x upper limit)	Admission platelets < 50 x10 ⁹ cells/L (4)
History of stroke	Hepatic failure (INR >1.5) (2.5)
History of bleeding or predisposition to bleeding	ICU/CCU stay (2.5)
Labile INR	Central venous catheter (2)
Alcohol or illicit drug use	Rheumatic disease (2)
Taking antiplatelet or NSAID	Active malignancy (2)
Age > 65	Age: 40-84 (1.5), ≥ 85 (3.5)
	Renal disease: GFR 30-59 mL/min (1), <30 mL/min (2.5)
High risk	High risk
≥ 3	≥ 7

[Return to last slide viewed](#)

[Table of contents](#)

References

1. [Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149\(2\):315-52.](#)
2. [Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141\(2 Suppl\):e419S-94S.](#)
3. [Enden T, Kløw NE, Sandvik L, et al. Catheter-directed thrombolysis vs. anticoagulant therapy alone in deep vein thrombosis: results of an open randomized, controlled trial reporting on short-term patency. J Thromb Haemost. 2009;7\(8\):1268-75.](#)
4. [Haig Y, Enden T, Grøtta O, et al. Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis \(CaVenT\): 5-year follow-up results of an open-label, randomised controlled trial. Lancet Haematol. 2016;3\(2\):e64-71.](#)
5. [Decousus H, Prandoni P, Mismetti P, et al. Fondaparinux for the treatment of superficial-vein thrombosis in the legs. N Engl J Med. 2010;363\(13\):1222-32.](#)
6. [Di nísio M, Wichers IM, Middeldorp S. Treatment for superficial thrombophlebitis of the leg. Cochrane Database Syst Rev. 2013;\(4\):CD004982.](#)
7. [Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368\(8\):699-708.](#)
8. [Kahn SR, Shapiro S, Wells PS, et al. Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. Lancet. 2014;383\(9920\):880-8.](#)
9. [Thompson G, Husney A, Ginsberg J. Leg Veins. Healthwise, Inc. 2015. Accessed online on Feb. 5, 2017. URL: <http://www.webmd.com/heart/superficial-and-deep-veins-of-the-leg>](#)
10. [Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med. 1998;338\(7\):409-15.](#)
11. [Mismetti P, Laporte S, Pellerin O, et al. Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial. JAMA. 2015;313\(16\):1627-35.](#)
12. [Bikdeli B, Ross JS, Krumholz HM. Data Desert for Inferior Vena Caval Filters: Limited Evidence, Supervision, and Research. JAMA Cardiol. 2017;2\(1\):3-4.](#)
13. [Righini M, Galanaud JP, Guenneguez H, et al. Anticoagulant therapy for symptomatic calf deep vein thrombosis \(CACTUS\): a randomised, double-blind, placebo-controlled trial. Lancet Haematol. 2016;3\(12\):e556-e562.](#)
14. [Franco L, Giustozzi M, Agnelli G, Becattini C. Anticoagulation in patients with isolated distal deep vein thrombosis: a meta-analysis. J Thromb Haemost. 2017;15\(6\):1142-1154.](#)
15. [Beyer-westendorf J, Schellong SM, Gerlach H, et al. Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial. Lancet Haematol. 2017;4\(3\):e105-e113.](#)
16. [Vedantham S, Goldhaber SZ, Julian JA, et al. Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis. N Engl J Med. 2017;377\(23\):2240-2252.](#)

[Return to last slide viewed](#)

[Table of contents](#)